Nivolumab meets primary endpoint in Phase 3 CheckMate -577 trial as adjuvant therapy for patients with resected oesophageal or gastroesophageal junction cancer

Treatment with nivolumab following neoadjuvant chemoradiation therapy and complete surgical resection demonstrated a statistically significant improvement in primary endpoint of disease free survival vs. placebo. Secondary endpoint of overall survival will be assessed later on.


Biospace Inc.